TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05179551

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proximal Medial Gastrocnemius Recession
Description: . A 3-4 cm transverse skin incision is made in the popliteal fossa, the superficial fascia is opened, and the medial gastrocnemius with its tendon (aponeurosis) is located. The tendon is then cut while lifting it with clamps, and care is taken to cut only the white tendon while sparing the underlying muscle. While performing a dorsiflexion movement of the ankle, careful palpation of the muscle is done to ensure that all tendon strands are cut completely. The incision is closed in layers, and only soft dressings applied
Study: NCT05728775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remimazolam is administered intravenously for induction and maintenance of general anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol is administered intravenously for induction and maintenance of general anesthesia.
Study: NCT05003336

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xiangshao Granules Placebo
Description: Xiangshao Granules Placebo
Study: NCT05321056

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: masks (surgical mask, respirator)
Description: The mask (surgical mask, respirator) will be worn on the face of the in vitro bionic model in the procedure room for measuring droplet exposure.
Study: NCT06512857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand puppet method
Description: Children in the experimental group were shown a hand puppet to distract them during the skin test for allergy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kaleidoscope method
Description: Children in the other experimental group were look at kaleidoscope to distract them during the skin test for allergy.
Study: NCT05640986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BART-EEG at V1 + V2
Description: Balloon Analogue Risk Task coupled to Electroencephalogram (BART-EEG) at V1 + V2 for Parkinsonian patients

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BART-EEG at V1 only
Description: Balloon Analogue Risk Task coupled to Electroencephalogram (BART-EEG) at V1 only for healthy volunteers
Study: NCT05829720

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: a2 Full Cream Milk
Description: Mothers in this arm will drink a2 Full Cream Milk twice a day, 200ml each time, for 14 consecutive days. Infants in this arm will be fed with mather's breastmilk exclusively.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Milk (Weidendorf)
Description: Mothers in this arm will drink Conventional Milk (Weidendorf) twice a day, 200ml each time, for 14 consecutive days. Infants in this arm will be fed with mather's breastmilk exclusively.
Study: NCT05581576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitolisant
Description: Pitolisant initial dose 8.9 mg, titrated depending on symptomatic response.
Study: NCT06474793

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aromatherapy Intervention Group-1
Description: For four weeks, once a day, 30 minutes before going to bed, a mixture of 3% chamomile and 3% lavender oil, diluted with 2% jojoba oil, is dropped into the palm of the palm of 2 ml, and after rubbing the hands together, rub the right and left nose for 4 minutes. It is the group that massages the edges of the hole with the index finger in circular movements from top to bottom, and then drops 2 ml of the oil mixture into the palm of the hand, rubs the hands mutually, and gently massages the edges of the ear with the index finger in circular movements from top to bottom behind the right and left ears for 4 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aromatherapy Intervention Group-2
Description: For four weeks, once a day, 30 minutes before going to bed, 3% vetiver oil diluted with 2% jojoba oil is dropped into the palm of the palm of 2 ml, and after rubbing the hands together, rub the edges of the right and left nostrils from top to bottom with the index finger for four minutes. It is a group where massage is applied with a massager and then 2 ml of the oil mixture is dropped into the palm of the hand, the hands are rubbed mutually, and then a gentle massage is applied behind the right and left ears with circular movements from top to bottom for 4 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Aromatherapy Placebo Control Group
Description: For four weeks, once a day, 30 minutes before going to bed, 2 ml of jojoba oil is dropped into the palm of the hand and after rubbing the hands mutually, massage the edges of the right and left nostril with circular movements from top to bottom with the index finger for four minutes and apply jojoba oil to the palm again. It is a group in which 2 ml is dropped and the hands are rubbed together and then gently massaged behind the right and left ears with circular movements from top to bottom for 4 minutes.
Study: NCT06014814

Intervention type: PROCEDURE
Intervention: Catheter ablation
Description: Catheter ablation of atrial fibrillation

Intervention type: PROCEDURE
Intervention: Catheter ablation
Description: Catheter ablation of atrial fibrillation
Study: NCT05847712

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated work in the heat
Description: Participants perform a continuous moderate-intensity work bout (metabolic rate of \~200 W/m2) until core temperature reaches 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels), which is immediately followed by intermittent work using a 3:1 work-rest allocation, starting with a 15 min rest break followed by a 45 min work bout for a total work duration of \~240 min. The work protocol is performed in the morning of day 1, and repeated in a post-lunch work period (i.e., afternoon of day 1) and on the morning of the next day (i.e., morning of day 2).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated work in the heat
Description: Participants perform a continuous moderate-intensity work bout (metabolic rate of \~200 W/m2) until core temperature reaches 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels), which is immediately followed by intermittent work using a 3:1 work-rest allocation, starting with a 15 min rest break followed by a 45 min work bout for a total work duration of \~240 min. The work protocol is performed in the morning of day 1, and repeated in a post-lunch work period (i.e., afternoon of day 1) and on the morning of the next day (i.e., morning of day 2).
Study: NCT05214846

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and counseling
Description: After obtaining informed consent, the data collection form, Hospital Anxiety Depression Scale (HADS) was applied to both groups by face to face interview. Immediately after the questionnaires were answered, individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. In addition, the education and counseling given to the participants by the researcher.The experimental group was given a telephone number where they could receive consultancy services for 12 hours a day. Pre-test was applied. One day later, the pregnant woman was called and encouraged to call for all her questions, and she was informed that she would be returned when she called.
Study: NCT05602311

Intervention type: DRUG
Intervention: General anesthetic
Description: Monitoring the changes of brain functional connectivity and assess cognition in two groups after general anesthesia

Intervention type: DRUG
Intervention: General anesthetic
Description: Monitoring the changes of brain functional connectivity and assess cognition in two groups after general anesthesia
Study: NCT05271279

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OVV-01 Injection+IBR900 Cell Injection
Description: 2 dose gradients are used for the OVV-01 injection, and the total infusion dose of IBR900 cell injection is 4.0×10\^9 cells per cycle.~OVV-01 injection will be first administered at W1D1 and then at W4D1 followed by every 2 weeks as a treatment cycle, for a total of 6 doses; after the test in the high-dose group is completed, the investigator and sponsor will determine whether to adjust the dosing frequency of OVV-01 (such as once a week) based on the result evaluations. The IBR900 cell injection will be first administered at W1D3 and W1D5 for 2 infusions, and then at W4D3 and W4D5, followed by every 4 weeks as a cycle, for a total of 4 doses, and cell infusions will be conducted at W1, W4, W8 and W12, respectively.
Study: NCT06042257

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guanfacine Hydrochloride Immediate Release
Description: 0.5 mg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule
Study: NCT05691283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: trans cranial direct current stimulation (tDCS)
Description: Three weeks of 20-minute tDCS stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: trans cranial direct current stimulation (tDCS)
Description: Three weeks of 20-minute tDCS stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham
Description: Three weeks of sham stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham
Description: Three weeks of sham stimulation
Study: NCT06191731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biological samples collection
Description: Urine samples are collected before Gd-CAs injection, and between 0- and two-and-a-half-hour post-injection of Gd-CAs.
Study: NCT04800523

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UroMonitor System
Description: Implantable device to wirelessly and without catheters monitor the neurogenic bladder on an ambulatory basis
Study: NCT04716881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone 380 MG
Description: Vivitrol (naltrexone) 380 mg delivered intramuscularly every 28 days
Study: NCT05758363

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Consumption of dietary supplement.
Description: Consumption of a dietary supplement rich in glutathione, selenium, zinc, vitamin D and EPA/DHA. 1 capsule per day of the dietary supplement with breakfast.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Consumption of control product
Description: Consumption of 1 capsule per day of control product of identical appearance with breakfast.
Study: NCT05658835

Intervention type: OTHER
Intervention: Thrombi and blood analyses
Description: Thrombi and blood will be collected during thrombectomy
Study: NCT05710510

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Local Care + Model
Description: Local primary care providers receive training in medical management of obesity prior to the start of the participant intervention.~Participants receive 6 quarterly clinic visits with their local primary care provider focused on medical management of obesity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Team Care Model
Description: Local primary care providers receive training in medical management of obesity prior to the start of the participant intervention.~Participants receive an intensive 18-month group lifestyle intervention (30 total sessions) led by a study lifestyle coach via Zoom, and 6 quarterly 1:1 visits via Zoom with their lifestyle coach. Participants also receive 6 quarterly clinic visits with their local primary care provider; the study lifestyle coach joins the visits via telemedicine. All three parties may meet via telemedicine if needed. The group lifestyle intervention is led by obesity treatment specialists with relevant graduate training and experience.
Study: NCT05539690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance training
Description: * Step-by-step training (5 levels)~* 30 minute per training~* 3 times per week~* 4 weeks
Study: NCT04739358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Subjects will receive tepotinib daily in cycles of 21-day duration. Subjects in the Combination Therapy arm will continue to receive their last tolerable dose of tyrosine kinase inhibitor (TKI) together with tepotinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Subjects will receive tepotinib daily in cycles of 21-day duration. Subjects in the Combination Therapy arm will continue to receive their last tolerable dose of tyrosine kinase inhibitor (TKI) together with tepotinib.
Study: NCT06351332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azenosertib
Description: WEE1 inhibitor, 25 or 100 mg tablet, taken orally per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azenosertib
Description: WEE1 inhibitor, 25 or 100 mg tablet, taken orally per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Platinum coordination compound, 5-, 15-, 45-, and 60-mL vials, via intravenous (into the vein) infusion per institutional standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Platinum coordination compound, 5-, 15-, 45-, and 60-mL vials, via intravenous (into the vein) infusion per institutional standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized immunoglobulin G4 monoclonal antibody, 4-mL vials, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized immunoglobulin G4 monoclonal antibody, 4-mL vials, via intravenous (into the vein) infusion per protocol.
Study: NCT04354025

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine induced memory-like NK cells
Description: -The CIML NK cells (maximum dose capped at 10 x 106/kg, minimum dose allowed is 0.5 x 106/kg) will be infused on Day 0 without a filter or pump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: -Fludarabine (dose: 30 mg/m\^2 per dose) will be given daily beginning on Day -7 for a total of 5 doses administered as an IV infusion over 30 minutes.
Study: NCT06249334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-body electrical stimulation
Description: The protocol with whole-body electrical stimulation will begin in the intensive care unit and will be completed in the inpatient unit. To stimulate all proposed muscle groups, self-adhesive electrodes will be positioned bilaterally on the quadriceps femoris, tibialis anterior, biceps brachii and lower rectus abdominis muscles. The frequency of 75 Hz will be adopted and the intensity will be adjusted to cause visible muscle contraction. The progression of the therapy protocol will occur throughout the sessions aiming to reach 20 minutes of therapy and 80 contractions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine physical therapy
Description: The protocol will be based on knee and hip flexion and extension movements; hip adduction and abduction; flexion and extension of shoulders, elbows and wrists; shoulder abduction and adduction; respecting the range of each joint. Volunteers will also perform transfers from lying to sitting and standing positions. Respiratory conduct will be based on ventilation patterns, bronchial hygiene maneuvers and cough.
Study: NCT06313983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay022+AI
Description: hemay022：orally once daily，A 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib+Capecitabine
Description: Take the pills according to the instructions
Study: NCT04745104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1707
Description: SHR-1707 will be administered through IV infusion
Study: NCT06548347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linperlisib
Description: Linperlisib at 80 mg orally once daily (QD) or 60mg orally once daily (QD) plus CHOP, placebo at 80mg or 60 mg orally once daily (QD) plus CHOP for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linperlisib
Description: Linperlisib at 80 mg orally once daily (QD) or 60mg orally once daily (QD) plus CHOP, placebo at 80mg or 60 mg orally once daily (QD) plus CHOP for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linperlisib
Description: Linperlisib at 80 mg orally once daily (QD) or 60mg orally once daily (QD) plus CHOP, placebo at 80mg or 60 mg orally once daily (QD) plus CHOP for 6 cycles
Study: NCT04745104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1707
Description: SHR-1707 will be administered through IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1707
Description: SHR-1707 will be administered through IV infusion
Study: NCT06548789

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic Xnack Packouts
Description: Prebiotic snack packouts (distributed every two weeks) and diet counseling to support increased consumption of prebiotic foods which provide dietary fiber, plant-based protein and other nutrients selectively fermented by the microbiome (e.g., pulses and legumes).
Study: NCT04745104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1707
Description: SHR-1707 will be administered through IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1707
Description: SHR-1707 will be administered through IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1707
Description: SHR-1707 will be administered through IV infusion
Study: NCT06563232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FNA group
Description: Fine-needle-aspiration (22G EchoTip Ultra Echo-3-22)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adapt FNB group
Description: Fine-needle-biopsy (22G Adapt Aspiration)
Study: NCT06563193

Intervention type: DIAGNOSTIC_TEST
Intervention: NERVE GROWTH FACTOR
Description: urinary neurotrophins
Study: NCT05513196

Intervention type: PROCEDURE
Intervention: Erector spinae plane block (ESPB)
Description: Bilateral erector spinae plane block will be performed with 20 mL, 0.25% bupivacaine at T9 level preoperatively.
Study: NCT06159647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mouth cancer warning
Description: Participants will view messages about the risk of mouth cancer from alcohol consumption.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Throat cancer warning
Description: Participants will view messages about the risk of throat cancer from alcohol consumption.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice box (larynx) warning
Description: Participants will view messages about the risk of voice box (larynx) cancer from alcohol consumption.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Esophagus cancer warning
Description: Participants will view messages about the risk of esophagus cancer from alcohol consumption.
Study: NCT05569954

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V116
Description: Sterile 0.5 mL solution in prefilled syringe containing 4 μg of each pneumococcal polysaccharide (PnPs) antigen 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23
Description: Sterile 0.5 mL solution in prefilled syringe containing 25 μg of each PnPs antigen 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.
Study: NCT05553210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOREST+
Description: The intervention will be delivered as an internet-based stress recovery intervention consisting of six weekly modules: introduction, psychological detachment, distancing, mastery, control, and keeping the change alive. Each module consists of a psychoeducational and an exercise component. During the program, a therapist provides individual feedback on the completed exercises and can also be available on request.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOREST+
Description: The intervention will be delivered as an internet-based stress recovery intervention consisting of six weekly modules: introduction, psychological detachment, distancing, mastery, control, and keeping the change alive. Each module consists of a psychoeducational and an exercise component. During the program, a therapist provides individual feedback on the completed exercises and can also be available on request.
Study: NCT04745104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered through IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered through IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered through IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered through IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered through IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered through IV infusion
Study: NCT04071470

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storytelling
Description: Couples in the storytelling intervention will receive 3 storytelling sessions- the couple can include any family or friends who they feel could support them during their treatment. Stories will include stories of couples who are supportive, those who experience difficulties, and families who do/do not support their use of PrEP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrEP
Description: Patients at risk of HIV acquisition will be provided PrEP medications and counseling in ANC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PrEP
Description: Patients at risk of HIV acquisition will be provided PrEP medications and counseling in ANC
Study: NCT05500027

Intervention type: DIAGNOSTIC_TEST
Intervention: serum test
Description: serum test of sCD58 and TGFbeta1

Intervention type: DIAGNOSTIC_TEST
Intervention: serum test
Description: serum test of sCD58 and TGFbeta1

Intervention type: DIAGNOSTIC_TEST
Intervention: serum test
Description: serum test of sCD58 and TGFbeta1

Intervention type: DIAGNOSTIC_TEST
Intervention: serum test
Description: serum test of sCD58 and TGFbeta1

Intervention type: DIAGNOSTIC_TEST
Intervention: serum test
Description: serum test of sCD58 and TGFbeta1
Study: NCT04509830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hip strengthening
Description: resistance training for hip abductor, hip extensor, and hip external rotator

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quadriceps strengthening, stretch hamstring,cuff muscles
Description: multi-angle isometric quadriceps strengthening and hamstring and cuff self stretch

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: quadriceps strengthening, stretch hamstring,cuff muscles
Description: multi-angle isometric quadriceps strengthening and hamstring and cuff self stretch